VEGFA and age-related macular degeneration: The introduction of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents has led to a reduction of 50% of patients with the neovascular form of AMD (nAMD) who end up blind; however, the group of patients, whose vision deteriorates despite receiving treatment, remains of great concern for clinicians [4].